The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback